Navigation Links
Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
Date:4/24/2008

PRINCETON, N.J., April 24 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Morgan Stanley Global Healthcare Unplugged Conference being held from April 30, 2008 to May 2, 2008 at the Ritz-Carlton Key Biscayne in Miami, Florida. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company and participate in a discussion moderated by Morgan Stanley representatives on Wednesday, April 30, 2008 at 3:40 PM (ET) in the Plaza Ballroom.

To access a simultaneous webcast of Mr. Price's overview and discussion via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation, if any, will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
2. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
3. Pharmasset Receives $10 Million of Working Capital
4. Pharmasset Appoints Herbert J. Conrad as a Director
5. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
6. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset Reports Fiscal Year End 2007 Financial Results
9. Pharmasset Appoints Michael Rogers as Chief Development Officer
10. Pharmasset to Present at Three Investor Conferences in November 2007
11. Pharmasset Accesses up to $30 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2013)... , Dec. 19, 2013  NeuroPhage Pharmaceuticals, ... an $822,000 grant by The Michael J. Fox ... drug candidate, NPT088, based on NeuroPhage,s GAIM (general ... misfolded proteins central to many neurodegenerative diseases. In ... research the effect of NPT088 on alpha-synuclein deposits ...
(Date:12/19/2013)... December 19, 2013 Top high school ... at the 55th Annual FiberMax® Caprock Classic in Lubbock, ... consecutive year that FiberMax cotton from Bayer CropScience has ... premier high school basketball tournaments. , The tournament is ... Clubs (AMBUCS), a nonprofit organization dedicated to creating independence ...
(Date:12/19/2013)... Mass. , Dec. 19, 2013  Decision Resources, ... for pharmaceutical and healthcare issues, finds that novel biologics ... with currently listed agents for a given disease to ... Argentina , Brazil ... the new Strategic Insights report entitled Trends ...
(Date:12/19/2013)... Finding a dead mouse in the lab ... lab is a Biosafety Level-3 containment facility designed to keep ... brain tumor that shines green under blue light, it’s time ... it’s time to panic. Especially when they could be spreading ... " Not Easy Being Green " is the second in ...
Breaking Biology Technology:NeuroPhage Awarded Second Grant from Michael J. Fox Foundation for Parkinson's Disease Research 2NeuroPhage Awarded Second Grant from Michael J. Fox Foundation for Parkinson's Disease Research 3NeuroPhage Awarded Second Grant from Michael J. Fox Foundation for Parkinson's Disease Research 455th Annual FiberMax Caprock Classic Basketball Tourney Is Largest in Nation 255th Annual FiberMax Caprock Classic Basketball Tourney Is Largest in Nation 355th Annual FiberMax Caprock Classic Basketball Tourney Is Largest in Nation 4New Biologics Must Show Improvements in Efficacy, Safety and Cost-Benefit Compared with Currently Available Agents for Inclusion on Formularies in Argentina, Brazil and Mexico 2A New Kind of Medical Thriller in Susy Gage's "Not Easy Being Green," Coming 2015 from Bitingduck Press 2
... Clinical Study Demonstrates Breakthrough Dose-Sparing Formulation,That Increases Stockpile ... Doses in a Pandemic Situation Sanofi pasteur, ... showing that its new investigational H5N1 pandemic influenza,vaccine ... response,at the lowest dose of H5N1 antigen reported ...
... often deal with the same problems, but they use ... can be difficult, if not impossible., A new $2.9 ... the National Science Foundation (NSF), will help bridge this ... solve common problems a range of scientists face., The ...
... 17 DaVita Inc.,(NYSE: DVA ) today announced ... Conference in London on Thursday, September 20, 2007 at ... access the live webcast, go to http://www.ibb.ubs.com, ... page, followed by the webcast link,listed next to the ...
Cached Biology Technology:Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 2Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 3Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 4Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 5CCMR gets $2.9M for training grad students in nanoscale science 2
(Date:12/19/2013)... Saint Louis University researchers have analyzed the microbiomes ... and found evidence that some chronic sinus issues ... an immune response to otherwise harmless microorganisms in ... in JAMA Otolaryngology - Head & Neck ... be the cause of most chronic rhinosinusitis (CRS) ...
(Date:12/19/2013)... Louisiana,s Barataria Bay have lung damage and adrenal ... populations, according to a new peer-reviewed study published ... Science & Technology . , The Deepwater Horizon ... conducted in August 2011 as part of the ... of government, academic and non-governmental researchers. In the ...
(Date:12/19/2013)... German . ... Centre for Genomic Regulation (CRG) in Barcelona, Spain, the Max ... (H. Lehrach) in Berlin and further partners from academia and ... for the first time the sweet genes of beetroot. The ... December in Nature , shed also light on how ...
Breaking Biology News(10 mins):With sinus study, Saint Louis University researchers find that harmless members of microbiome spark immune reaction 2With sinus study, Saint Louis University researchers find that harmless members of microbiome spark immune reaction 3Deepwater Horizon NRDA study shows possible oil impact on dolphins 2Deepwater Horizon NRDA study shows possible oil impact on dolphins 3Deciphering the secret of the sugar beet 2
... University of Jerusalem has discovered a way to literally catch ... Prof. Joseph Almog of the Hebrew University,s Casali Institute of ... on cotton swabs taken from the hands of a suspect, ... chemical will turn a blood red hue. Urea nitrate ...
... of an ancient growing medium has implications for advancing ... conditions. Greek research scientists Dr. George Gizas and ... of pumice to determine the most effective particle size ... Pumice, an inert mineral of volcanic origin, has been ...
... Specialties,Inc. (Nasdaq: MEAS ), a designer and manufacturer ... recently adopted German,Business Tax Reform 2008 on current year ... which became effective on August,17, 2007, reduces the corporate ... the combined German tax rate from approximately 39% to ...
Cached Biology News:HU scientist finds way to catch terrorists red-handed 2Measurement Specialties, Inc. Announces Impact of 'German Business Tax Reform 2008' Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results 2Measurement Specialties, Inc. Announces Impact of 'German Business Tax Reform 2008' Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results 3
Mouse monoclonal [2991] to C3a / C3a des Arg ( Abpromise for all tested applications). SwissProtID: P01024...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Purified anti-PI3K p110 delta...
Peptide-affinity Purified Polyclonal Antibody to Histamine H2 Receptor...
Biology Products: